en · de · es · fr · pt
sr9009-notes.peptides4800.com › Blog › Analytical Detection And Laboratory Handling — Questions and Answers

Analytical Detection And Laboratory Handling — Questions and Answers

By Editorial Desk · published 2025-11-19 · last reviewed 2025-12-04 · Blog

HPLC-UV comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2025-12-04. Numbers and descriptions here follow the published literature rather than marketing material.

Analytical Detection and Laboratory Handling

Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.

Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.

In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.

Background and Receptor Mechanism

Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.

Sr9009 at a glance

PropertyValueNotes
AppearanceOff-white to pale yellow solidVisual description varies with purity and source
SolubilitySoluble in DMSO and ethanol; poorly soluble in waterOrganic stock solutions are common in research
Typical storage-20 °C, desiccated, protected from lightAvoid repeated freeze-thaw cycles
Typical analytical methodLC-MS or HPLC-UVReference standards are needed for quantification
Molar massApproximately 437.9 g/molCalculated from the reported free-base formula

Detection, Regulation, and Misconceptions

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.

Related pages on this site

SR9009 Background and Mechanism

Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.

In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.

Regulation, Testing, and Storage

Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.

SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.

Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.

Background and Receptor Pharmacology

Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.

Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.

Background from the literature

== Production == GnIH neurons reside primarily in the dorsomedial nucleus of the hypothalamus (humans and rodents) and the paraventricular nucleus of the hypothalamus (avian species). Some GnIH neuron terminals in both mammalian and avian species project to the median eminence. GnIH and GnRH (gonadotropin releasing hormone) neurons exist in close proximity in the hypothalamus, which may enable the direct inhibition of GnRH neurons by GnIH. GnIH enters the bloodstream via the hypothalamo-hypophyseal portal system, the vascular network supplying both the hypothalamus and the pituitary. GnIH and GnIH receptor (GnIH-R) mRNA is expressed in the hypothalamus, pituitary, and ovaries. GnIH expression is highest during proestrus and lowest during estrus, suggesting the estrus cycle influences release of the hormone. Furthermore, GnIH neuronal cell counts in multiple vertebrates fluctuate with an organism's parental status. GnIH cell count may also vary with breeding season in some species. For instance, European starlings (Sturnus vulgaris) with greater reproductive success exhibited higher quantities of GnIH-producing cells than did those that were less successful, but this effect did not appear until mid-breeding season.

German South West Africa was established in 1884. After World War I, the League of Nations gave South West Africa, formerly a German colony, to the United Kingdom as a mandate under the administration of South Africa. When the National Party won the 1948 election in South Africa and subsequently introduced apartheid legislation, these laws were also applied to South West Africa which was considered the de facto fifth province of South Africa. SWAPO was founded on 19 April 1960 as the successor of the Ovamboland People's Organization. Leaders renamed the party to show that it represented all Namibians. But, the organisation had its base among the Ovambo people of northern Namibia, who constituted nearly half the total population.

Polysaccharides containing alpha-(1-4)-linked D-glucose units + H2O (specific for alpha-(1-4)-linkages, requirements for non-reducing chain end) Starch + H2O Amylopectin + H2O Glycogen Amylose + H2O Alpha-D-glucopyranosyl-(1-4)-2-deoxy-D-glucal (maltal) Inhibitors include Glucose, Maltose (competitive), Alpha-methyl-glucoside, Cyclodextrins (e.g. cyclohexaamylose), o-Iodosobenzoate, Ag+, Hg2+, Cu2+, N-Ethylmaleimide, p-Chloromercuribenzoate (reversed by DTT or mercaptoethanol, reversed by glutathione), Pb2+, Ni2+, Cd2+, Fe3+, Zn2+, Mn2+, Mg2+, EDTA, Beta-amylase inhibitor (from Streptomyces sp. No. 54), K2PtCl6, K2PtCl4, K2IrCl6, Na2PdCl6, CO32-, and Iodoacetamide.

=== Personal information === Personally identifying information, financial information like credit card and bank account information, and medical data from medical data breaches is bought and sold, mostly in darknet markets but also in other black markets. People increase the value of the stolen data by aggregating it with publicly available data, and sell it again for a profit, increasing the damage that can be done to the people whose data was stolen.

=== Executive committee === The management of the Society is vested in an Executive Committee made up of Officers and General Members, they also act as Trustees of the Society. There are currently 10 officers of the Society namely the Chair, Vice-Chair, Treasurer, General Secretary, Meetings Secretary, Papers Secretary, Education Officer, Publicity Secretary, Special Interest Group Co-ordinator, and Digital Communications Officer.

Sources: en.wikipedia.org

Further detail

=== 1996–2004: Hiatus, side projects and death of Layne Staley === Although Alice in Chains never officially disbanded, Staley became a recluse, rarely leaving his Seattle condominium following the death of his ex-fiancée Demri Parrott on October 29, 1996. "Drugs worked for me for years," Staley told Rolling Stone in February 1996, "and now they're turning against me ... now I'm walking through hell and this sucks. I didn't want my fans to think that heroin was cool. But then I've had fans come up to me and give me the thumbs up, telling me they're high. That's exactly what I didn't want to happen." Unable to continue with new Alice in Chains material, Cantrell released his first solo album, Boggy Depot, in 1998, also featuring Sean Kinney and Mike Inez. Cantrell and Kinney were also featured on Metallica's 1998 album Garage Inc., both were guest musicians in the track "Tuesday's Gone", a Lynyrd Skynyrd cover. In October 1998, Staley reunited with Alice in Chains to record two new songs, "Get Born Again" and "Died". Originally intended for Cantrell's second solo album, the songs were reworked by Alice in Chains and were released in the fall of 1999 on a box set, Music Bank. The set contains 48 songs, including rarities, demos, and previously released album tracks and singles. The band also released a 15-track compilation titled Nothing Safe: Best of the Box, serving as a sampler for Music Bank, as well as the band's first compilation album; a live album, simply titled Live, released on December 5, 2000; and a second compilation, titled Greatest Hits in 2001.

=== Brazil === The R2 Combat Operation Ration (Portuguese: Ração Operacional de Combate – R2) is the current field & combat ration for the Brazilian Army. It is based on the earlier, but similar, Alternative Combat Ration for 24 Hours (Portuguese: Ração Alternativa de Combate, 24 horas) developed by the Brazilian Navy for use by Naval Infantry units. It contains the food and supplemental items needed by 1 soldier for 24 hours. It is to be used in situations where no other type of ration is available. All foods are packed inside 4-ply plastic and aluminum polylaminate retort pouches and are ready to eat without further preparation. The ration is packed inside a heavy-duty (.25 mm thick) matte green or olive drab polyethylene bag measuring 300 mm wide by 400 mm long. It is printed with the logo of the Brazilian Army, the name of the ration, and menu information. Inside are 5 thinner (.10 mm) semi-transparent plastic bags, one for each meal and one for the accessories. Each bag is printed with meal information and contents.

== June 16, 1915 (Wednesday) == Second Battle of Artois — French soldiers pushed towards Vimy Ridge but were held up as many German defense positions survived bombardment. British and Canadian forces launched a second attack north of La Bassée, France and a new attack on Bellewaarde, France, but failed to reach both objectives. Bussa rebellion — A revolt broke out in the town of Bussa, Nigeria following British Northern Nigeria Protectorate's decision to replace the Emir of Bussa with a bayt al-mal (native administration). The colonial capital received word that 600 rebels led by a local prince had attacked and killed half of the members of bayt al-mal and occupied the town. Despite a shortage of British colonial troops, the revolt was suppressed quickly with minimal casualties. The British Women's Institute was established. The association football club Lemense was founded in Leme, São Paulo, Brazil. The club was dissolved and revived twice in its history, first in 1967 and again in 2005. Born: Mariano Rumor, Italian state leader, 39th Prime Minister of Italy; in Vicenza, Kingdom of Italy (present-day Italy) (d. 1990) Lucy Dawidowicz, American historian, popular expert on modern Jewish history including The Holocaust, author of The War Against the Jews; as Lucy Schildkret, in New York City, United States (d.

=== Hari Dhar === Hari Dhar (Nabhaan Rizwan) is a new grad assigned to Pierpoint's IBD desk alongside Gus. Having come from a family of Indian immigrants and graduated from a state school, Hari feels out of place among Pierpoint's new grads, and overcompensates by working through the night at the office, sleeping in the bathrooms, skipping nights out with his colleagues, and abusing energy drinks and stimulant pills to stay awake. Within days, Hari dies of a heart attack in Pierpoint's bathroom stalls. Pierpoint does brief damage control before going back to business as usual. However, Hari's death causes many Pierpoint employees to reflect on the cutthroat culture of investment banking, and plays a role in Gus' eventual decision to leave the firm.

In 2005, Katja Seipel and Volker Schmid suggested that cnidarians and ctenophores are simplified descendants of triploblastic animals, since ctenophores and the medusa stage of some cnidarians have striated muscle, which in bilaterians arises from the mesoderm. They did not commit themselves on whether bilaterians evolved from early cnidarians or from the hypothesized triploblastic ancestors of cnidarians. Resolving the evolutionary relationships within Cnidaria has also been challenging, with almost every possible combination of clades being proposed. As time went on though, a semi-consensus has started to emerge. The enigmatic Polypodium hydriforme and subphylum Myxozoa have been firmly placed within the Cnidaria and have been shown to be closely related to the Medusozoa. In addition, these two groups have been found to likely be each other's closest relatives which, if true, would form the clade "Endocnidozoa". The relationships within the Medusozoa are currently probably the most contentious part of the tree. Traditionally, the class Scyphozoa also included Staurozoa and Cubozoa, but significant morphological differences eventually lead to the split of the three. The group containing them has since been named "Acraspeda". The relationships between these three and Hydrozoa have since and still are debated. A relationship between Scyphozoa and Cubozoa with Staurozoa as its sister has seen support in nearly all studies, but the position of the remaining class, Hydrozoa, is not understood.

Sources: en.wikipedia.org

Frequently asked questions

How is SR9009 detected?

It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.

What is known about its stability?

The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.

Why does solubility matter?

Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.

What is SR9009?

SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.

Network